Varda Space Industries, a startup focused on space-based manufacturing, has signed pharmaceutical company United Therapeutics as a client for orbital drug experiments, marking what could be a significant milestone in commercial space manufacturing.

The partnership represents one of the first major pharmaceutical companies to commit to space-based drug development, potentially validating the business model that Varda has been promoting. The startup specializes in performing manufacturing processes in the microgravity environment of space, which proponents argue can produce materials with different properties than those created on Earth.

Space-based manufacturing has been an area of growing interest as launch costs have decreased and access to orbit has become more routine. The unique conditions of space, particularly the absence of gravity, can potentially allow for the creation of materials and pharmaceutical compounds that are difficult or impossible to produce on Earth.

Varda's approach involves using automated manufacturing platforms that can operate in space and return products to Earth. The company has been working to demonstrate that orbital manufacturing can be commercially viable for high-value products like pharmaceuticals.

Industry observers suggest this partnership could signal a turning point for space manufacturing, as major pharmaceutical companies begin to seriously consider orbital production as part of their development strategies. The success of this collaboration may influence whether other pharmaceutical companies pursue similar space-based manufacturing arrangements.